Loading market dashboard
Profusa, Inc. Common Stock
PFSAHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
BERKELEY, CA, May 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces that, effective May 15, 2026, the Company will now be listed on The Nasdaq Capital Market. The move is the first of a previously announced series of interim milestones as laid out by the Nasdaq Hearings Panel to ensure continued compliance with the bid price and stockholders' equity requirements for continued listing on the Capital Market tier.
BERKELEY, CA, May 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announced that, by letter dated May 6, 2026, the Nasdaq Hearings Panel granted the Company's request to transfer the listing of its securities from The Nasdaq Global Market to The Nasdaq Capital Market.
BERKELEY, CA, May 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announced that, by letter dated May 6, 2026, the Nasdaq Hearings Panel granted the Company's request to transfer the listing of its securities from The Nasdaq Global Market to The Nasdaq Capital Market. The Company's continued listing on Nasdaq is subject to the Company's satisfaction of certain interim milestones and, ultimately, the Company's compliance with the bid price and stockholders' equity requirements for continued listing on the Capital Market tier by July 6, 2026.
Company focusing resources on near-term commercial milestones; European CE Mark process and Healthcare Research revenue opportunities Process intended to evaluate strategic growth alternatives to enhance scale, strengthen execution and support long-term shareholder value creation BERKELEY, CA, May 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announced that its Board of Directors has initiated a Board-led process to evaluate strategic alternatives intended to maximize shareholder value and support the Company's highest-priority commercial, regulatory and platform-expansion initiatives. The process will evaluate a range of potential opportunities, including asset-level transactions, commercial and strategic partnerships, business combinations and other corporate transactions.
Profusa ($PFSA) shares down 40% to $1.10. Company signs LOI for $30M acquisition to scale its diagnostics and monitoring business.
Company secures scalable multi-omics diagnostics platform and launches Mayo Clinic partnership adding to Lumee real-time biochemistry monitoring platform to advance pancreatic cancer applications BERKELEY, CA, April 06, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, today announced a strategic expansion into molecular diagnostics through a Letter of Intent to acquire the PanOmics™ multi-omics diagnostics platform from BioInsights LLC (“BioInsights”). The Company believes this acquisition, adding to its core real-time biochemistry monitoring platform, will help to position Profusa at the intersection of biosensing, diagnostics, and precision medicine, establishing a foundation for scalable multi-product diagnostics and monitoring franchise.
Applied Optoelectronics Inc (NASDAQ: AAOI) rose in pre-market trading after securing an 800G transceiver order worth $71 million, bringing total orders from a major customer to $124 million. Other gainers include Xiao-I Corp (NASDAQ: AIXI), Profusa Inc (NASDAQ: PFSA), and Soleno Therapeutics Inc (NASDAQ: SLNO). Losers include Intercont (Cayman) Ltd (NASDAQ: NCT), Visionary Holdings Inc (NASDAQ: GV), and PMGC Holdings Inc (NASDAQ: ELAB).
Medline (NASDAQ: MDLN - Get Free Report) and Profusa (NASDAQ: PFSA - Get Free Report) are both manufacturing companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk. Profitability This table compares Medline and Profusa's net margins, return
